Detection and neutralisation of heparin by a fluorescent ruthenium compound

Heparin and low-molecular-weight heparin (LMWH) are commonly monitored by determination of activated clotting times or chromogenic assays. Despite their wide use, these assays determine the biological activity and not the concentration of the anticoagulants. They may be inaccurate in some circumstan...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 102; no. 5; p. 859
Main Authors Szelke, Helga, Harenberg, Job, Krämer, Roland
Format Journal Article
LanguageEnglish
Published Germany 01.11.2009
Subjects
Anticoagulants - antagonists & inhibitors
Anticoagulants - blood
Blood Coagulation Tests
Chromogenic Compounds - analysis
Drug Design
Drug Monitoring - methods
Factor Xa - analysis
Factor Xa Inhibitors
Fiber Optic Technology
Fluorescent Dyes - analysis
Heparin Antagonists - pharmacology
Heparin, Low-Molecular-Weight - antagonists & inhibitors
Heparin, Low-Molecular-Weight - blood
Humans
Molecular Structure
Oligopeptides - analysis
Organometallic Compounds - analysis
Organometallic Compounds - chemical synthesis
Organometallic Compounds - chemistry
Point-of-Care Systems
Sensitivity and Specificity
Spectrometry, Fluorescence - methods
Online AccessGet more information

Cover

More Information
Summary:Heparin and low-molecular-weight heparin (LMWH) are commonly monitored by determination of activated clotting times or chromogenic assays. Despite their wide use, these assays determine the biological activity and not the concentration of the anticoagulants. They may be inaccurate in some circumstances such as certain disease states. In addition, there is a significant interest in alternative tests for the point-of-care detection of heparin and LMWH. Their binding to small molecules for the detection in biological matrices is poorly explored. We describe here a new optical molecular probe for the detection of LMWH in serum samples. The polycationic ruthenium compound 1 is applicable to the quantification of heparin by monitoring 630 nm fluorescence. In addition, compound 1 is a rare example of a non-polymeric low molecular weight compound which neutralises the anticoagulant activity of heparin and LMWH in plasma samples. Limitation of the method is its low sensitivity currently being improved by structural modification of compound 1.
ISSN:0340-6245
DOI:10.1160/TH09-03-0168